Akebia Therapeutics Inc. Insider Trading

AKBA

⊜ Compare

Last 12 months

Insiders bought 87K and sold 963K on the open market.

All of the selling was scheduled in advance under 10b5-1 plans.

Net open-market

−876K

1 buy · 7 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

1 / 6

executives and directors

Last open-market buy

Mar 2026

Mar 4, 2026

Get an email when AKBA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 29	Erik Ostrowski SVP, CFO, CBO & Treasurer	Sold10b5-1 plan	56,019	$1.11	62K	8.3%	Form 4
Mar 4	John P. Butler CEO and President	Bought	69,270	$1.25	87K	2.0%	Form 4
Feb 2	Carolyn M. Rucci SVP, Chief Legal Officer	Sold10b5-1 plan 3 parts	69,772	$1.39 average	97K	11%	Form 4
Feb 2	Richard C Malabre SVP, Chief Accounting Officer	Sold10b5-1 plan 2 parts	49,524	$1.39 average	69K	14%	Form 4
Feb 2	Erik Ostrowski SVP, CFO, CBO & Treasurer	Sold10b5-1 plan	34,951	$1.39	49K	4.9%	Form 4
Feb 2	Nicholas Grund Chief Commercial Officer	Sold10b5-1 plan 2 parts	84,829	$1.39 average	118K	13%	Form 4
Feb 2	Steven Keith Burke SVP, Chief Medical Officer	Sold10b5-1 plan 3 parts	67,658	$1.39 average	94K	6.7%	Form 4
Feb 2	John P. Butler CEO and President	Sold10b5-1 plan 4 parts	341,305	$1.39 average	474K	9.0%	Form 4
Jun 30, 2025	Erik Ostrowski SVP, CFO, CBO & Treasurer	Sold10b5-1 plan	41,314	$3.67	152K	7.6%	Form 4
Jun 9, 2025	Richard C Malabre SVP, Chief Accounting Officer	Sold10b5-1 plan	15,000	$4.01	60K	5.3%	Form 4
Jun 4, 2025	Richard C Malabre SVP, Chief Accounting Officer	Sold10b5-1 plan	13,334	$3.53	47K	4.8%	Form 4
Mar 3, 2025	John P. Butler CEO and President	Sold10b5-1 plan	46,409	$1.83	85K	1.6%	Form 4
Mar 3, 2025	Steven Keith Burke SVP, Chief Medical Officer	Sold10b5-1 plan	7,144	$1.83	13K	0.9%	Form 4
Feb 3, 2025	John P. Butler CEO and President	Sold10b5-1 plan 2 parts	144,250	$2.10 average	303K	4.7%	Form 4
Feb 3, 2025	Steven Keith Burke SVP, Chief Medical Officer	Sold10b5-1 plan 2 parts	50,506	$2.10 average	106K	5.8%	Form 4
Feb 3, 2025	Richard C Malabre SVP, Chief Accounting Officer	Sold10b5-1 plan	30,202	$2.10	63K	9.7%	Form 4
Feb 3, 2025	Nicholas Grund Chief Commercial Officer	Sold10b5-1 plan	55,621	$2.10	117K	11%	Form 4

Jun 2910b5-1 plan
Erik Ostrowski
SVP, CFO, CBO & Treasurer · sold 56,019 at $1.11
62K
8.3% of stake
Mar 4
John P. Butler
CEO and President · bought 69,270 at $1.25
87K
2.0% of stake
Feb 210b5-1 plan
Carolyn M. Rucci
SVP, Chief Legal Officer · sold 69,772 at avg $1.39
97K
11% of stake
Feb 210b5-1 plan
Richard C Malabre
SVP, Chief Accounting Officer · sold 49,524 at avg $1.39
69K
14% of stake
Feb 210b5-1 plan
Erik Ostrowski
SVP, CFO, CBO & Treasurer · sold 34,951 at $1.39
49K
4.9% of stake
Feb 210b5-1 plan
Nicholas Grund
Chief Commercial Officer · sold 84,829 at avg $1.39
118K
13% of stake
Feb 210b5-1 plan
Steven Keith Burke
SVP, Chief Medical Officer · sold 67,658 at avg $1.39
94K
6.7% of stake
Feb 210b5-1 plan
John P. Butler
CEO and President · sold 341,305 at avg $1.39
474K
9.0% of stake
Jun 30, 202510b5-1 plan
Erik Ostrowski
SVP, CFO, CBO & Treasurer · sold 41,314 at $3.67
152K
7.6% of stake
Jun 9, 202510b5-1 plan
Richard C Malabre
SVP, Chief Accounting Officer · sold 15,000 at $4.01
60K
5.3% of stake
Jun 4, 202510b5-1 plan
Richard C Malabre
SVP, Chief Accounting Officer · sold 13,334 at $3.53
47K
4.8% of stake
Mar 3, 202510b5-1 plan
John P. Butler
CEO and President · sold 46,409 at $1.83
85K
1.6% of stake
Mar 3, 202510b5-1 plan
Steven Keith Burke
SVP, Chief Medical Officer · sold 7,144 at $1.83
13K
0.9% of stake
Feb 3, 202510b5-1 plan
John P. Butler
CEO and President · sold 144,250 at avg $2.10
303K
4.7% of stake
Feb 3, 202510b5-1 plan
Steven Keith Burke
SVP, Chief Medical Officer · sold 50,506 at avg $2.10
106K
5.8% of stake
Feb 3, 202510b5-1 plan
Richard C Malabre
SVP, Chief Accounting Officer · sold 30,202 at $2.10
63K
9.7% of stake
Feb 3, 202510b5-1 plan
Nicholas Grund
Chief Commercial Officer · sold 55,621 at $2.10
117K
11% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AKBA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with AKBA

CompareIntrinsic value

IDYAIdeaya Biosciences Inc.

$32.36+3.29%40

VNDAVanda Pharmaceuticals Inc.

$3.88+3.47%10

PBYIPuma Biotechnology Inc.

$10.69+4.60%68

ANABAnaptysBio Inc.

$47.51-0.46%20

MRVIMaravai Lifesciences Holdings Inc.

$7.72+3.62%10

RCUSArcus Biosciences Inc.

$19.31+2.12%10

PHATPhathom Pharmaceuticals Inc.

$5.68-1.05%10

RYTMRhythm Pharmaceuticals Inc.

$110.68+28.04%40

Held by ETFs

AKBA is in 11 US ETFs. The largest of them, with AKBA's weight in each:

Spot a number that looks wrong? Check it in AKBA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AKBA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.